Postoperative PainANIPAPNCT07566663
Preventive Analgesia With Anrikefon in Laparoscopic Cholecystectomy
A study testing Anrikefon for Preventive Analgesia and Anrikefon for bridging analgesia in people with Postoperative Pain, run by Xuanwu Hospital, Beijing at 1 site in China.
Trial summary
This study will determine the optimal timing for Anrikefon administration. It will also assess the quality of patient recovery. Laparoscopic cholecystectomy (LC) is a routine surgical procedure. However, the incidence of acute visceral and incision pain is high, reaching 50% to 70%. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Postoperative Pain
- What is being tested?
- Anrikefon for Preventive Analgesia and Anrikefon for bridging analgesia
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 274 participants
- Where
- 1 siteChina
- Study dates
- 2 Jun 2026to 30 Jun 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- ASA physical status classification I-III;
- Age 18-65 years;
- Scheduled for elective laparoscopic cholecystectomy;
- Voluntary signed informed consent;
- BMI between 18-28 kg/m²;
- No history of general anesthesia surgery within the past 3 months.
Who cannot join
- Severe cardiovascular disease, respiratory disease, or psychiatric disorders;
- Severe renal insufficiency;
- Recent use of diuretics or compound medications containing diuretics;
- Continuous use of opioid analgesics for more than 10 days within the past 3 months;
- Use of medications with unknown half-life affecting analgesic efficacy within 14 days prior to randomization;
- Pregnant women, lactating women, or those planning pregnancy in the near future;
- History of hypersensitivity to study medications.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Xuanwu Hospital, Capital Medical University
Beijing, Beijing Municipality, 100053
Wei Xiao, 8613810971299, kitten15@126.com
About this study
Official title: Effect of Preventive Analgesia With Anrikefon on Postoperative Acute Pain and Rehabilitation Process in Adult Patients Undergoing Laparoscopic Cholecystectomy
This study will determine the optimal timing for Anrikefon administration. It will also assess the quality of patient recovery. Laparoscopic cholecystectomy (LC) is a routine surgical procedure. However, the incidence of acute visceral and incision pain is high, reaching 50% to 70%. This pain significantly impairs patient recovery.
Anrikefon is novel peripherally restricted κ-opioid receptor agonist. It has very low brain penetration. This property reduces central nervous system side effects and respiratory depression. Preventive analgesia blocks the transmission of nociceptive stimuli to the central nervous system. It reduces postoperative pain sensitization and intensity. Currently, research on Anrikefon for preventive analgesia in LC patients is limited. It impacts on the recovery process is not yet fully understood. This study will compare drug administration before anesthesia induction with intra-operative administration.
Read more
Participants will be assigned to one of two groups with equal probability using computer-generated random numbers. Patients in the Preventive Analgesia group will receive Anrikefon injection 15 minutes before anesthesia induction. Bridging Analgesia group is the control group. Patients in this group will receive Anrikefon immediately after the gallbladder is detached from the liver. Both groups will receive the identical drug dosage of 1 μg/kg.
Both treatment groups will receive identical care beyond the time of Anrikefon administration. All patients will undergo standardized anesthesia management. Parecoxib sodium 40 mg will be injected for rescue analgesia if NRS score > 4. We will analyze the primary, secondary, and exploratory outcome measures after surgery, aiming to explore the optimal timing of Anrikefon and its impact on the patient's recovery process.
Read the detailed description
This study is a prospective, double-blinded, randomized controlled study. Adult patients (18-65 years old) who are planning to receive Laparoscopic Cholecystectomy will be enrolled into this study, and will be randomly divided according to 1:1. They will be named the preventive analgesia group and the bridging analgesia group. Primary end point is the time-weighted sum of pain intensity differences over 0-24 hours postoperatively (SPID₀-₂₄h) , which will be calculated according to the NRS scores at every time point(after surgery immediately ,15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 20 hours, and 24 hours).
- Conditions
- Postoperative Pain
- Being tested
- Anrikefon for Preventive Analgesia, Anrikefon for bridging analgesia
- Keywords
- Preventive Analgesia, Laparoscopic Cholecystectomy, Postoperative Acute Pain, Visceral Pain, Anrikefon
- Medical subject headings
- Pain, Postoperative, Visceral Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Anrikefon for Preventive AnalgesiaDrug
The Preventive Analgesia Group will receive intravenous Anrikefon (1 μg/kg) 15 minutes before anesthesia induction. Each bolus administration should be completed within 2 minutes ± 5 seconds.
Anrikefon for bridging analgesiaDrug
The Bridging Analgesia Group will receive intravenous Anrikefon (1 μg/kg) immediately after the gallbladder is removed from the liver bed. Each bolus administration should be completed within 2 minutes ± 5 seconds.
| Study group | Role | What they receive |
|---|---|---|
| Preventive Analgesia Group | Experimental | Patients in Preventive Analgesia Group will receive intravenous Anrikefon (1 μg/kg) at 15 minutes before anesthesia induction. Each bolus administration should be completed within 2 minutes ± 5 seconds. Receives: Drug: Anrikefon for Preventive Analgesia |
| Bridging Analgesia Group | Active comparator | Patients in Bridging Analgesia Group will receive intravenous Anrikefon (1 μg/kg) immediately after the gallbladder is dissected from the liver bed. Each bolus administration should be completed within 2 minutes ± 5 seconds. Receives: Drug: Anrikefon for bridging analgesia |
What is being measured
The primary outcome is the main question the study is designed to answer.
The time-weighted sum of pain intensity differences over 0-24 hours postoperatively of visceral pain
The time-weighted sum of pain intensity differences over 0-24 hours postoperatively (SPID₀-₂₄h) will be calculated through Numerical Rating Scale (NRS) scores. NRS scores ranges from 0 to 10 of visceral pain. It will be assessed immediately after surgery, and at 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 20 hours, and 24 hours postoperatively. SPID₀-₂₄h will be calculated based on the NRS scores at each time point. Higher SPID₀-₂₄h will indicate better analgesic efficacy. The formula is: SPID₀-₂₄h = Σ[(Baseline NRS - NRS at time point) × Δt]. Δt represents the time interval between two consecutive assessments.
Measured: From the end of surgery to 24 hours postoperatively
Secondary outcomes (11)
The time-weighted sum of pain intensity differences over 0-24 hours postoperatively of Incisional pain
The time-weighted sum of pain intensity differences over 0-24 hours postoperatively (SPID₀-₂₄h) will be calculated through Numerical Rating Scale (NRS) scores. NRS scores ranges from 0 to 10 of incisional pain. It will be assessed immediately after surgery, and at 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 20 hours, and 24 hours postoperatively. SPID₀-₂₄h will be calculated based on the NRS scores at each time point. Higher SPID₀-₂₄h will indicate better analgesic efficacy. The formula is: SPID₀-₂₄h = Σ[(Baseline NRS - NRS at time point) × Δt]. Δt represents the time interval between two consecutive assessments.
Measured: From the end of surgery to 24 hours postoperatively
The Numerical Rating Scale scores for visceral pain and incisional pain
The Numerical Rating Scale (NRS) scores ranges from 0 to 10. NRS scores of visceral pain and incisional pain will be recorded immediately after surgery, and 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 20 hours, and 24 hours postoperatively. Higher scores will indicate more severe pain.
Measured: From the end of surgery to 24 hours postoperatively
Duration of postoperative incisional pain and visceral pain
The duration from surgery completion to the timepointing when NRS score is< 3 .
Measured: From the end of surgery to 72 hours postoperatively
Total Oxycodone consumption of the postoperative analgesia pump
The consumption of Oxycodone in the patient-controlled analgesia (PCA) pump will be recorded.
Measured: From the end of surgery to 48 hours postoperatively
Total Parecoxib sodium for rescue analgesia after surgery
If patients' NRS score was greater than 4, they will receive Parecoxib for rescue analgesia. The total dose of parecoxib will be recorded.
Measured: From the end of surgery to 72 hours postoperatively
15-item Quality of Recovery scale
15-item Quality of Recovery scale (QOR-15) is used to assess postoperative recovery quality. The total score ranging from 0 to 150. Higher scores will indicate better postoperative recovery and lower scores will indicate poorer recovery.
Measured: at Day 1 and Day 3 after surgery
Recovery of gastrointestinal function
The duration from end of surgery to first flatus and first oral intake .
Measured: From the end of surgery to Day 3 after surgery
Intake, Feeling nauseated, Emesis, Exam, and Duration of symptoms scoring system score
Intake, Feeling nauseated, Emesis, Exam, and Duration of symptoms scoring system (I-FEED) . The I-FEED score will assess postoperative gastrointestinal function based on Intake, Feeling nauseated, Emesis, physical Exam, and Duration of symptoms. Total score ranges from 0 to 12. Higher scores will indicate worse postoperative nausea and vomiting (PONV) status.
Measured: 24 hours, 48 hours, and 72 hours after surgery
Length of hospital stay
The duration of hospitalization will be calculated from the day of hospital admission to the day of discharge. The total number of hospital days will be recorded.
Measured: From the day of hospital admission to the day of discharge, on anverage of 3-5 days.
Rate of adverse reactions and complications
Adverse reactions will include postoperative nausea and vomitting, Constipation, Sedation, Somnolence, Respiratory Depression, Psychiatric Symptoms, Urinary Retention, Allergic Reactions, Intraoperative Awareness, Intraoperative Hypotension, Intraoperative Hypertension, Intraoperative Bradycardia, Intraoperative Tachycardia, Laryngospasm, Anaphylaxis, Postoperative Hypotension, Postoperative Hypertension, Postoperative Bradycardia, and Postoperative Tachycardia. Complications will include Arrhythmia, Cardiac Arrest, Myocardial Infarction, Myocardial Injury, Pneumonia, Cardiogenic Pulmonary Edema, Pulmonary Embolism, Delirium, Stroke, Acute Kidney Injury, Gastrointestinal Bleeding, Paralytic Ileus, Deep Vein Thrombosis and Infection.
Measured: From anesthesia induction to 72 hours after surgery
30 days mortality
any death of patients occur in 30 days after surgery
Measured: from the end of surgery to 30 days after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 May 2026
- Study start2 Jun 2026
- Primary completion31 May 2028 (estimated)
- Study completion30 Jun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Postoperative PainStudies of the same condition, open and under way.
- More trials run by Xuanwu Hospital, BeijingThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This study will employ a prospective, parallel-group, randomized controlled, single-center design with double-blind assessment. Randomization will occur prior to surgery.It will use computer-generated random numbers to assign patients in a 1:1 ratio to either the Preventive Analgesia group or the Bridging Analgesia group. Allocation concealment will follow a rigorous sequential procedure: randomization codes will be placed in sequentially numbered, opaque envelopes attached to case report forms. When an eligible patient is ready for anesthesia. The anesthesiologist will prepare and administer the study drug according to the assigned timing protocol. Group allocation will bes kept confidential from patients and statisticians.
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 274 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Xuanwu Hospital, Beijing
- Sponsor type
- University, hospital or other
- Collaborators
- Haisco Pharmaceutical Group Co., Ltd.
- Responsible party
- Sponsor
- Investigators
- Wei Xiao, Principal investigator, Xuanwu Hospital, BeijingTianlong Wang, Principal investigator, Xuanwu Hospital, Beijing
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07566663
- Sponsor's protocol ID
- Linyanshen[2026]008-002
- Acronym
- ANIPAP
- Status last verified
- Jun 2026
- First submitted
- 20 Apr 2026
- Last updated
- 1 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Preventive Analgesia With Anrikefon on Postoperative Acute Pain and Rehabilitation Process in Adult Patients Undergoing Laparoscopic Cholecystectomy
- ClinicalTrials.gov ID
- NCT07566663
- Acronym / sponsor ID
- ANIPAP / Linyanshen[2026]008-002
- Conditions
- Postoperative Pain
- Keywords
- Preventive Analgesia, Laparoscopic Cholecystectomy, Postoperative Acute Pain, Visceral Pain, Anrikefon
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 274 participants (estimated)
- Lead sponsor
- Xuanwu Hospital, BeijingUniversity, hospital or other
- Collaborators
- Haisco Pharmaceutical Group Co., Ltd.
- Study start
- 2 Jun 2026 (actual)
- Primary completion
- 31 May 2028 (estimated)
- Study completion
- 30 Jun 2028 (estimated)
- First posted
- 5 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will determine the optimal timing for Anrikefon administration. It will also assess the quality of patient recovery. Laparoscopic cholecystectomy (LC) is a routine surgical procedure. However, the incidence of acute visceral and incision pain is high, reaching 50% to 70%. This pain significantly impairs patient recovery.
Anrikefon is novel peripherally restricted κ-opioid receptor agonist. It has very low brain penetration. This property reduces central nervous system side effects and respiratory depression. Preventive analgesia blocks the transmission of nociceptive stimuli to the central nervous system. It reduces postoperative pain sensitization and intensity. Currently, research on Anrikefon for preventive analgesia in LC patients is limited. It impacts on the recovery process is not yet fully understood. This study will compare drug administration before anesthesia induction with intra-operative administration.
Participants will be assigned to one of two groups with equal probability using computer-generated random numbers. Patients in the Preventive Analgesia group will receive Anrikefon injection 15 minutes before anesthesia induction. Bridging Analgesia group is the control group. Patients in this group will receive Anrikefon immediately after the gallbladder is detached from the liver. Both groups will receive the identical drug dosage of 1 μg/kg.
Both treatment groups will receive identical care beyond the time of Anrikefon administration. All patients will undergo standardized anesthesia management. Parecoxib sodium 40 mg will be injected for rescue analgesia if NRS score > 4. We will analyze the primary, secondary, and exploratory outcome measures after surgery, aiming to explore the optimal timing of Anrikefon and its impact on the patient's recovery process.
Detailed description
This study is a prospective, double-blinded, randomized controlled study. Adult patients (18-65 years old) who are planning to receive Laparoscopic Cholecystectomy will be enrolled into this study, and will be randomly divided according to 1:1. They will be named the preventive analgesia group and the bridging analgesia group. Primary end point is the time-weighted sum of pain intensity differences over 0-24 hours postoperatively (SPID₀-₂₄h) , which will be calculated according to the NRS scores at every time point(after surgery immediately ,15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 20 hours, and 24 hours).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
- Model description
- This study will employ a prospective, parallel-group, randomized controlled, single-center design with double-blind assessment. Randomization will occur prior to surgery.It will use computer-generated random numbers to assign patients in a 1:1 ratio to either the Preventive Analgesia group or the Bridging Analgesia group. Allocation concealment will follow a rigorous sequential procedure: randomization codes will be placed in sequentially numbered, opaque envelopes attached to case report forms. When an eligible patient is ready for anesthesia. The anesthesiologist will prepare and administer the study drug according to the assigned timing protocol. Group allocation will bes kept confidential from patients and statisticians.
| Arm | Type | Receives |
|---|---|---|
| Preventive Analgesia Group | Experimental | Drug: Anrikefon for Preventive AnalgesiaPatients in Preventive Analgesia Group will receive intravenous Anrikefon (1 μg/kg) at 15 minutes before anesthesia induction. Each bolus administration should be completed within 2 minutes ± 5 seconds. |
| Bridging Analgesia Group | Active comparator | Drug: Anrikefon for bridging analgesiaPatients in Bridging Analgesia Group will receive intravenous Anrikefon (1 μg/kg) immediately after the gallbladder is dissected from the liver bed. Each bolus administration should be completed within 2 minutes ± 5 seconds. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- ASA physical status classification I-III;
- Age 18-65 years;
- Scheduled for elective laparoscopic cholecystectomy;
- Voluntary signed informed consent;
- BMI between 18-28 kg/m²;
Key exclusion criteria (7 listed)
- Severe cardiovascular disease, respiratory disease, or psychiatric disorders;
- Severe renal insufficiency;
- Recent use of diuretics or compound medications containing diuretics;
- Continuous use of opioid analgesics for more than 10 days within the past 3 months;
- Use of medications with unknown half-life affecting analgesic efficacy within 14 days prior to randomization;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Anrikefon for Preventive AnalgesiaThe Preventive Analgesia Group will receive intravenous Anrikefon (1 μg/kg) 15 minutes before anesthesia induction. Each bolus administration should be completed within 2 minutes ± 5 seconds. | Drug | Preventive Analgesia Group |
| Anrikefon for bridging analgesiaThe Bridging Analgesia Group will receive intravenous Anrikefon (1 μg/kg) immediately after the gallbladder is removed from the liver bed. Each bolus administration should be completed within 2 minutes ± 5 seconds. | Drug | Bridging Analgesia Group |
Primary outcome
The time-weighted sum of pain intensity differences over 0-24 hours postoperatively of visceral pain
Time frame: From the end of surgery to 24 hours postoperatively
The time-weighted sum of pain intensity differences over 0-24 hours postoperatively (SPID₀-₂₄h) will be calculated through Numerical Rating Scale (NRS) scores. NRS scores ranges from 0 to 10 of visceral pain. It will be assessed immediately after surgery, and at 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 20 hours, and 24 hours postoperatively. SPID₀-₂₄h will be calculated based on the NRS scores at each time point. Higher SPID₀-₂₄h will indicate better analgesic efficacy. The formula is: SPID₀-₂₄h = Σ[(Baseline NRS - NRS at time point) × Δt]. Δt represents the time interval between two consecutive assessments.
11 secondary outcomes
The time-weighted sum of pain intensity differences over 0-24 hours postoperatively of Incisional pain
Time frame: From the end of surgery to 24 hours postoperatively
The Numerical Rating Scale scores for visceral pain and incisional pain
Time frame: From the end of surgery to 24 hours postoperatively
Duration of postoperative incisional pain and visceral pain
Time frame: From the end of surgery to 72 hours postoperatively
Total Oxycodone consumption of the postoperative analgesia pump
Time frame: From the end of surgery to 48 hours postoperatively
Total Parecoxib sodium for rescue analgesia after surgery
Time frame: From the end of surgery to 72 hours postoperatively
15-item Quality of Recovery scale
Time frame: at Day 1 and Day 3 after surgery
Recovery of gastrointestinal function
Time frame: From the end of surgery to Day 3 after surgery
Intake, Feeling nauseated, Emesis, Exam, and Duration of symptoms scoring system score
Time frame: 24 hours, 48 hours, and 72 hours after surgery
Length of hospital stay
Time frame: From the day of hospital admission to the day of discharge, on anverage of 3-5 days.
Rate of adverse reactions and complications
Time frame: From anesthesia induction to 72 hours after surgery
30 days mortality
Time frame: from the end of surgery to 30 days after surgery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Postoperative Pain
RecruitingPhase 4
ESP Blocks for Posterior Spinal Fusion
Postoperative Pain
Recruiting
Effect of Cryotherapeutic and Nanotherapeutic Sodium Hypochlorite on Post-Operative Endodontic Pain.
Symptomatic Irreversible Pulpitis, Symptomatic Apical Periodontitis
RecruitingPhase 2
REctus Sheath Trial
Acute Pain, Postoperative Pain, Acute
Not yet recruiting
Effect of Pectoral Nerve Block (PECS) Using Magnesium Sulfate Added to Dexamethasone on Quality of Recovery and Chronic Post-Mastectomy Pain
Breast Cancer, Postoperative Pain
Active, not recruitingPhase 4
Effect of Dexmedetomidine on Postoperative Pain in Spinal Anesthesia for Cesarean Section at Assuit University Hospital
Cesarean Section
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Wei Xiao principal investigator
Xuanwu Hospital, Beijing
Tianlong Wang principal investigator
Xuanwu Hospital, Beijing
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Anrikefon for Preventive Analgesia and Anrikefon for bridging analgesia in people with Postoperative Pain, run by Xuanwu Hospital, Beijing at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 1 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Wei Xiao, PhD (+8613810971299, kitten15@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The time-weighted sum of pain intensity differences over 0-24 hours postoperatively of visceral pain (time frame: From the end of surgery to 24 hours postoperatively). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jul 2026.